These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 16625840)

  • 1. Medicinal chemistry of somatostatin analogs leading to the DTPA and DOTA conjugates of the multi-receptor-ligand SOM230.
    Lewis I; Albert R; Kneuer R; Pless J; Simeon C; Kerrad S; Hoyer D; Bruns C
    J Endocrinol Invest; 2005; 28(11 Suppl International):15-20. PubMed ID: 16625840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy.
    Froidevaux S; Heppeler A; Eberle AN; Meier AM; Häusler M; Beglinger C; Béhé M; Powell P; Mäcke HR
    Endocrinology; 2000 Sep; 141(9):3304-12. PubMed ID: 10965902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switch from antagonist to agonist after addition of a DOTA chelator to a somatostatin analog.
    Reubi JC; Erchegyi J; Cescato R; Waser B; Rivier JE
    Eur J Nucl Med Mol Imaging; 2010 Aug; 37(8):1551-8. PubMed ID: 20396884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin analogs and radiopeptides in cancer therapy.
    Froidevaux S; Eberle AN
    Biopolymers; 2002; 66(3):161-83. PubMed ID: 12385036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential.
    Lewis I; Bauer W; Albert R; Chandramouli N; Pless J; Weckbecker G; Bruns C
    J Med Chem; 2003 Jun; 46(12):2334-44. PubMed ID: 12773038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [DOTA]Somatostatin-14 analogs and their (111)In-radioligands: effects of decreasing ring-size on sst1-5 profile, stability and tumor targeting.
    Tatsi A; Maina T; Cescato R; Waser B; Krenning EP; de Jong M; Cordopatis P; Reubi JC; Nock BA
    Eur J Med Chem; 2014 Feb; 73():30-7. PubMed ID: 24378707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of different spacers on the biological profile of a DOTA-somatostatin analogue.
    Antunes P; Ginj M; Walter MA; Chen J; Reubi JC; Maecke HR
    Bioconjug Chem; 2007; 18(1):84-92. PubMed ID: 17226960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SOM230: a new therapeutic modality for Cushing's disease.
    Lewis I; Schmid HA; Kneuer R; Hoyer D; Silva AP; Weckbecker G; Bruns C; Pless J
    Chimia (Aarau); 2014; 68(7-8):483-4. PubMed ID: 25437387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors.
    Hasskarl J; Kaufmann M; Schmid HA
    Future Oncol; 2011 Jul; 7(7):895-913. PubMed ID: 21732759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro.
    Lesche S; Lehmann D; Nagel F; Schmid HA; Schulz S
    J Clin Endocrinol Metab; 2009 Feb; 94(2):654-61. PubMed ID: 19001514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
    Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
    J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin receptor subtypes in human non-functioning neuroendocrine tumors and effects of somatostatin analogue SOM230 on cell proliferation in cell line NCI-H727.
    Ono K; Suzuki T; Miki Y; Taniyama Y; Nakamura Y; Noda Y; Watanabe M; Sasano H
    Anticancer Res; 2007; 27(4B):2231-9. PubMed ID: 17695508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs.
    Weckbecker G; Briner U; Lewis I; Bruns C
    Endocrinology; 2002 Oct; 143(10):4123-30. PubMed ID: 12239124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SOM230 inhibits insulin-like growth factor-I action in mammary gland development by pituitary independent mechanism: mediated through somatostatin subtype receptor 3?
    Ruan W; Fahlbusch F; Clemmons DR; Monaco ME; Walden PD; Silva AP; Schmid HA; Kleinberg DL
    Mol Endocrinol; 2006 Feb; 20(2):426-36. PubMed ID: 16223973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential indications for somatostatin analogs in Cushing's syndrome.
    Arnaldi G; Polenta B; Cardinaletti M; Boscaro M
    J Endocrinol Invest; 2005; 28(11 Suppl International):106-10. PubMed ID: 16625858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas.
    Batista DL; Zhang X; Gejman R; Ansell PJ; Zhou Y; Johnson SA; Swearingen B; Hedley-Whyte ET; Stratakis CA; Klibanski A
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4482-8. PubMed ID: 16940446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Labeling of oligonucleotides with DTPA and DOTA on solid phase.
    Hovinen J
    Nucleosides Nucleotides Nucleic Acids; 2007; 26(10-12):1459-62. PubMed ID: 18066806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Indium-111-DTPA-phenyl-pentetreotide somatostatin receptors' scintigraphy in the evaluation of patients with suspected gastro-entero-pancreatic tumors. Comparison with computerized tomography].
    Gerasimou GP; Aggelopoulou T; Papanastasiou E; Konidari-Dedousi E; Prousalidis I; Psarrakos K; Siountas A; Molybda E; Gotzamani-Psarrakou A
    Hell J Nucl Med; 2007; 10(3):209-14. PubMed ID: 18084669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.
    Hofland LJ; van der Hoek J; Feelders R; van Aken MO; van Koetsveld PM; Waaijers M; Sprij-Mooij D; Bruns C; Weckbecker G; de Herder WW; Beckers A; Lamberts SW
    Eur J Endocrinol; 2005 Apr; 152(4):645-54. PubMed ID: 15817922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors.
    Schmid HA; Schoeffter P
    Neuroendocrinology; 2004; 80 Suppl 1():47-50. PubMed ID: 15477717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.